QuidelOrtho Misses Q1 Revenue by $45M, Slashes Full-Year Outlook Amid Weak Demand
QDEL is trading near its 52-week low of $10.86 (5.8% above the low).
Summary
QuidelOrtho reported a significant miss for its first-quarter 2026 results, with revenue of $619.8 million falling approximately $45 million short of analyst expectations and an adjusted loss of $0.04 per share against a $0.40 consensus. The company also sharply cut its full-year 2026 revenue guidance from a prior range of $2.7-$2.9 billion to $2.70-$2.75 billion, and adjusted EBITDA guidance from $630-$670 million to $615-$630 million. This negative financial update, driven by a weak respiratory season and disruptions in China and the Middle East, extends the challenging performance seen in fiscal year 2025, where the company reported a substantial net loss. The material misses and reduced outlook are highly actionable for traders, signaling a deteriorating business environment and likely leading to significant downward pressure on the stock. Traders will be watching for further clarity on the impact of China's IVD pricing guidelines and the company's strategy to address declining demand in key segments.
At the time of this announcement, QDEL was trading at $11.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $793.8M. The 52-week trading range was $10.86 to $38.99. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.